Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 282

1.

A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.

Perahia DG, Quail D, Gandhi P, Walker DJ, Peveler RC.

J Affect Disord. 2008 May;108(1-2):33-41.

PMID:
17905442
2.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.

J Psychiatr Res. 2008 Jan;42(1):22-34.

PMID:
17445831
3.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18.

PMID:
17559729
4.

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.

J Psychiatr Res. 2005 Jan;39(1):43-53.

PMID:
15504423
5.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
6.

An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.

Wohlreich MM, Martinez JM, Mallinckrodt CH, Prakash A, Watkin JG, Fava M.

J Clin Psychopharmacol. 2005 Dec;25(6):552-60.

PMID:
16282837
7.

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K.

J Clin Psychiatry. 2007 Nov;68(11):1707-16.

PMID:
18052564
8.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ.

Eur Psychiatry. 2006 Sep;21(6):367-78.

PMID:
16697153
9.

Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.

Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG.

J Affect Disord. 2006 Aug;94(1-3):183-9.

PMID:
16780958
10.

A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.

Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, Gonzales JS, Greist JH.

J Clin Psychiatry. 2007 Dec;68(12):1921-30.

PMID:
18162024
11.

Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.

Wohlreich MM, Mallinckrodt CH, Watkin JG, Wilson MG, Greist JH, Delgado PL, Fava M.

Ann Clin Psychiatry. 2005 Oct-Dec;17(4):259-68.

PMID:
16402760
12.

Duloxetine in the long-term treatment of major depressive disorder.

Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB.

J Clin Psychiatry. 2003 Oct;64(10):1237-44.

PMID:
14658974
13.

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.

Clin Drug Investig. 2007;27(7):481-92.

PMID:
17563128
14.

Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.

Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD.

J Clin Psychiatry. 2011 Aug;72(8):1086-94. doi: 10.4088/JCP.09m05723blu.

PMID:
20868642
15.

A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.

Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.

Curr Med Res Opin. 2011 Oct;27(10):1849-58. doi: 10.1185/03007995.2011.609539.

PMID:
21838411
16.

A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.

Kornstein SG, Dunner DL, Meyers AL, Whitmyer VG, Mallinckrodt CH, Wohlreich MM, Detke MJ, Hollandbeck MS, Greist JH.

J Clin Psychiatry. 2008 Sep;69(9):1383-92.

PMID:
19193339
17.

Management of depression relapse: re-initiation of duloxetine treatment or dose increase.

Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D.

J Psychiatr Res. 2006 Jun;40(4):328-36.

PMID:
16678205
18.

Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.

Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C.

J Clin Psychopharmacol. 2008 Feb;28(1):32-8. doi: 10.1097/jcp.0b013e318160738e.

PMID:
18204338
19.

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA.

J Psychiatr Res. 2002 Nov-Dec;36(6):383-90.

PMID:
12393307
20.

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.

Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV.

Hum Psychopharmacol. 2005 Jul;20(5):327-41. Review.

PMID:
15912562

Supplemental Content

Support Center